Peers and Perspectives

A panel of urologic and oncologic experts provide comprehensive insights on optimal utilization of androgen deprivation therapy in patients with prostate cancer, highlighting the evolving treatment landscape and recent clinical trial data.

Trinity Bivalacqua, MD, PhD, and Mark Tyson, MD, MPH, discuss key conversation points surrounding high-risk BCG-unresponsive NMIBC as presented at ASCO 2024 in Chicago, Illinois.

Neal Shore, MD, FACS, and Brian M. Shuch, MD, have a comprehensive discussion on the evolving imaging and diagnostic landscape in kidney cancer, highlighting emerging PET imaging agents.

Matthew Smith, MD, PhD, and Brian T. Helfand, MD, have a comprehensive discussion on the treatment of patients with prostate cancer, highlighting the treatment of nonmetastatic CRPC and metastatic HSPC and the role of AR pathway inhibitors.

Christopher M. Pieczonka, MD and Jose De La Cerda, MD, MPH engage in a comprehensive discussion on the nuances of abiraterone formulations for treating metastatic castration-resistant prostate cancer (mCRPC). They explore patient assessment, treatment considerations for special populations, and clinical practice management tailored to the diverse needs of patients with mCRPC.

Michelle Semins, MD, and Seth Bechis, MD, explore recent advancements in treating urinary stones, focusing on the significance of intrarenal pressure (IRP), its effect on patient outcomes, and methods to decrease elevated IRP.

Experts David Morris, MD, FACS, and Benjamin Garmezy, MD, share a dynamic discussion on the respective roles of combination therapy and multidisciplinary care in the current treatment landscape of advanced prostate cancer.

Key opinion leaders discuss the latest PSMA-PET imaging updates for prostate cancer and consider how real-world practice has evolved.

This Uroview features discussion between Dr. Alexandra Rogers and Dr. Scott MacDiarmid about current and emerging treatments for overactive bladder, with a focus on implantable tibial nerve stimulation devices in this space.

Steven Finkelstein, MD, DABR, FACRO, and Louis J. Mazzarelli, MD, react to the article, “A Prospective Head-to-Head Comparison of 18F-Fluciclovine With 68Ga-PSMA-11 in Biochemical Recurrence of Prostate Cancer in PET/CT,” by Pernthaler B, et al.

Two experts in urology provide a discussion on currently available screening and risk assessment tools in prostate cancer and emphasize the importance of early detection.

Analysis of Gallium-68 PSMA 9 (prostate-specific membrane antigen) targeted PET (positron emission tomography) imaging and its impact on staging and prostate cancer.

Specialists in urology discuss the significance of germline testing in prostate cancer.